What triggered Moderna shares' latest price pullback

Traders Union
All News
Financial News
Moderna slides 2.08% today to $51.28

Highlights

Moderna shares saw volatility as five-year follow-up data for its cancer vaccine mRNA-4157 showed continued progress, balancing a 33% quarterly revenue decline from lower COVID-19 vaccine sales.
A $2.25 billion patent settlement eased legal uncertainty, but insider selling and unclear commercialization timelines have kept pressure on the stock.
Technical analysis signals high short-term volatility with MRNA trading below resistance, but upward bias persists with an 80% probability of a near-term rally toward the $56.94–$57.29 range.

Broader selling persists amid vaccine pipeline progress and legal settlement

Moderna reported significant volatility in 2026, with key drivers including positive data from a five-year follow-up of a mid-stage study on its investigational cancer vaccine, mRNA-4157. The company posted a 33% year-over-year revenue decline in the fourth quarter as COVID-19 vaccine demand decreased and is advancing a pipeline of mRNA-based vaccines, with a flu vaccine currently under regulatory review in the United States. A $2.25 billion patent settlement was reached to resolve legal disputes related to mRNA technology use, while insider selling and uncertainty regarding product commercialization timelines have been noted, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees growing caution around Moderna stock. He notes that negative price action below the MA-20 and a 33% revenue decline are serious warnings. Kharitonov is skeptical about the impact of positive cancer vaccine news, given persistent selling pressure and insider selling. He highlights that strong technical signals are undermined by conflicting oversold conditions and still-high volatility. "Sustained uncertainty and unresolved risks make any bullish scenario fragile for now," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, believes Moderna maintains a constructive outlook despite recent volatility. He sees the pipeline depth and regulatory milestones as critical for future growth. Karapetjanc notes the patent settlement lifts an overhang and provides investors with added confidence. He emphasizes the high probability of a near-term price rebound, supported by strong trend and momentum signals. "Bullish structure remains intact, and further growth can be expected as new products reach market," Karapetjanc states.

Parshwa Turakhiya, analyst, observes that current market sentiment is driven by high volatility and news around new vaccine data. He notes strong technical divergence, with bullish momentum clashing against intraday selling and oversold readings. Turakhiya highlights that support near $48.11 is crucial for short-term setups. "These conditions create unique opportunities for traders watching for sharp reversals and fast-moving breakouts," Turakhiya explains.

Oversold signals clash with bullish momentum as intraday volatility rises

Momentum analysis shows that MACD remains strongly bullish and ADX signals a robust upward trend, but there is a divergence as Stoch RSI and BBP highlight strong oversold conditions, indicating sellers dominate intraday. RSI on D1 is just above mid-levels, and CCI reads neutral, while AO is neutral and does not reinforce the short-term direction. The price has slipped 2.08% today with a mild gap down at the open, currently sitting near the daily low in a relatively wide intraday range, suggesting high volatility and continued pressure after the opening.

Previously it was reported that while Moderna’s longer-term trend remained resilient, short-term selling pressure and mixed momentum signals introduced a layer of caution. The current analysis both expands on and reinforces this caution, highlighting continued volatility alongside a notably high probability of a price recovery, with market participants advised to monitor the $52.94–$53 resistance zone as a trigger for renewed bullish momentum.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.